News brief.
The quality and quantity of drug safety reporting is largely insufficient, according to a recent study supported by the Agency for Healthcare Research and Quality and published in the January 24/31 Journal of the American Medical Association. The survey looked at nearly 200 drug trials and found that the severity of side effects was satisfactorily explained in less than half of them.
Jeanne Sabatie. Drug safety story not complete.
Business and Health
2001;3:10.
Positive Results for Ruxolitinib Cream in Children with Atopic Dermatitis Presented in Ongoing Study
March 18th 2024Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Read More
FDA Updates for Week of March 11: First CAR-T for CLL/SLL and First NASH Treatment
March 16th 2024The FDA this week approved a few firsts: the first treatment for NASH and the first CAR-T cell therapy for CLL/SLL. Other approvals include Tevimbra for esophageal cancer; Livmarli for second liver disease indication; and Praluent for children with genetic form of high cholesterol. The FDA also issued a CRL for monthly MS drug. Additionally, Celltrion submitted an application for an interchangeable Xolair biosimilar.
Read More
A Deep Dive into Predictive and Generative AI with Lynn Carroll of HSBlox
January 3rd 2024In this month’s episode, Briana Contreras, an editor of MHE, chatted with Lynn Carroll, executive of HSBlox, about the difference between predictive and generative AI, yet how each works together in preventive healthcare.
Listen
Transforming the management of genetic testing
March 15th 2024This e-book will explain where the current genetic test management system is inadequate and how a new approach designed specifically for genetic testing will perform better and provide more meaningful and actionable results.
Read More